TWI850365B - 治療克隆氏症(crohn's disease)的方法 - Google Patents

治療克隆氏症(crohn's disease)的方法 Download PDF

Info

Publication number
TWI850365B
TWI850365B TW109112447A TW109112447A TWI850365B TW I850365 B TWI850365 B TW I850365B TW 109112447 A TW109112447 A TW 109112447A TW 109112447 A TW109112447 A TW 109112447A TW I850365 B TWI850365 B TW I850365B
Authority
TW
Taiwan
Prior art keywords
weeks
dose
milikizumab
administered
treatment
Prior art date
Application number
TW109112447A
Other languages
English (en)
Chinese (zh)
Other versions
TW202103734A (zh
Inventor
史都華 威廉 菲來得利奇
保羅 弗雷德里克 波勒克
杰 勞倫斯 圖透
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202103734A publication Critical patent/TW202103734A/zh
Application granted granted Critical
Publication of TWI850365B publication Critical patent/TWI850365B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW109112447A 2019-04-22 2020-04-14 治療克隆氏症(crohn's disease)的方法 TWI850365B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
US62/836,910 2019-04-22

Publications (2)

Publication Number Publication Date
TW202103734A TW202103734A (zh) 2021-02-01
TWI850365B true TWI850365B (zh) 2024-08-01

Family

ID=70554215

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109112447A TWI850365B (zh) 2019-04-22 2020-04-14 治療克隆氏症(crohn's disease)的方法
TW113124301A TW202515610A (zh) 2019-04-22 2020-04-14 治療克隆氏症(crohn's disease)的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113124301A TW202515610A (zh) 2019-04-22 2020-04-14 治療克隆氏症(crohn's disease)的方法

Country Status (21)

Country Link
US (1) US20220040299A1 (enExample)
EP (3) EP3958897B1 (enExample)
JP (3) JP7297930B2 (enExample)
KR (2) KR20250153865A (enExample)
CN (2) CN119700968A (enExample)
AU (2) AU2020263238C1 (enExample)
BR (1) BR112021018930A2 (enExample)
DK (1) DK3958897T3 (enExample)
EA (1) EA202192532A1 (enExample)
ES (1) ES3075314T3 (enExample)
FI (1) FI3958897T3 (enExample)
IL (2) IL286818B2 (enExample)
LT (1) LT3958897T (enExample)
MA (1) MA55756A (enExample)
MX (1) MX2021012848A (enExample)
PT (1) PT3958897T (enExample)
SG (1) SG11202110619XA (enExample)
TW (2) TWI850365B (enExample)
UA (1) UA128657C2 (enExample)
WO (1) WO2020219314A1 (enExample)
ZA (1) ZA202108094B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722474A (zh) * 2015-09-18 2017-07-01 百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20160031983A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
WO2018035330A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
EP3652539A4 (en) * 2017-07-10 2021-03-31 Rambam Med-Tech Ltd. ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODIES IN ORGANIC MEDICINE TREATED PATIENTS AND USES THEREOF IN PERSONALIZED MEDICINE
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722474A (zh) * 2015-09-18 2017-07-01 百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Ma, Christopher, et al. "Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease." Expert Opinion on Investigational Drugs 27.8 (2018): 649-660. *

Also Published As

Publication number Publication date
CN113677366A (zh) 2021-11-19
BR112021018930A2 (pt) 2022-01-18
EP3958897A1 (en) 2022-03-02
JP7761614B2 (ja) 2025-10-28
ZA202108094B (en) 2025-05-28
TW202515610A (zh) 2025-04-16
AU2020263238B2 (en) 2023-08-17
AU2020263238C1 (en) 2024-02-22
WO2020219314A1 (en) 2020-10-29
EP4778573A2 (en) 2026-07-22
CN119700968A (zh) 2025-03-28
EP3958897B1 (en) 2026-05-06
PT3958897T (pt) 2026-07-17
KR20250153865A (ko) 2025-10-27
AU2020263238A1 (en) 2021-11-04
SG11202110619XA (en) 2021-11-29
IL286818A (en) 2021-10-31
EA202192532A1 (ru) 2022-01-21
JP2025148449A (ja) 2025-10-07
EP4789714A2 (en) 2026-08-12
UA128657C2 (uk) 2024-09-18
KR102869852B1 (ko) 2025-10-14
NZ781127A (en) 2025-06-27
MX2021012848A (es) 2021-12-10
DK3958897T3 (da) 2026-07-20
JP7297930B2 (ja) 2023-06-26
US20220040299A1 (en) 2022-02-10
TW202103734A (zh) 2021-02-01
LT3958897T (lt) 2026-08-10
AU2023265759A1 (en) 2023-12-07
JP2023116680A (ja) 2023-08-22
ES3075314T3 (en) 2026-08-03
FI3958897T3 (fi) 2026-07-16
IL286818B1 (en) 2025-11-01
KR20210142704A (ko) 2021-11-25
MA55756A (fr) 2022-03-02
IL286818B2 (en) 2026-03-01
JP2022530397A (ja) 2022-06-29
CA3134587A1 (en) 2020-10-29
IL324048A (en) 2025-12-01

Similar Documents

Publication Publication Date Title
AU2023248103B2 (en) Methods of treating ulcerative colitis
JP2025148449A (ja) クローン病を治療する方法に使用するためのミリキズマブ
CA3134587C (en) Mirikizumab for use in a method of treating crohn's disease
EA045979B1 (ru) Мирикизумаб для применения в способе лечения болезни крона
EA049081B1 (ru) Способы лечения язвенного колита